Targets › IL13
5 programs from 5 companies in 20 trials: 13 Phase 3, 4 Phase 2, 2 Phase 4, 1 Phase 1; Immunology, Respiratory, Other; next expected readout Nov 2026.
Cytokine that plays important roles in allergic inflammation and immune response to parasite infection. Synergizes with IL2 in regulating interferon-gamma synthesis. (UniProt, P35225)
Open in Phaseline: the race on IL13, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Eli Lilly | Lebrikizumab (LY3650150) Interleukin-13 inhibitor | IL13 | Phase 4 | Atopic Dermatitis; Chronic Rhinosinusitis With Nasal Polyps (CRSwNP); Perennial Allergic Rhinitis (PAR) | Dec 2026 |
| Pfizer | tilrekimig (PF-07275315) IL-13 receptor alpha-1 antagonist | IL13 | Phase 3 | Atopic Dermatitis; Asthma; Moderate to Severe Chronic Obstructive Pulmonary Disease; Healthy | Nov 2026 |
| Almirall | Lebrikizumab Interleukin-13 inhibitor | IL13 | Phase 3 | Dermatitis, Atopic; Nummular Eczema | Apr 2027 |
| AstraZeneca | Tozorakimab Dose Regimen 1 IL-13 receptor antagonist | IL13 | Phase 3 | Viral Lung Infection and Acute Respiratory Failure; Chronic Obstructive Pulmonary Disease; Asthma | Jun 2027 |
| LEO Pharma | Tralokinumab Interleukin-13 inhibitor | IL13 | Phase 3 | Atopic Dermatitis | Apr 2028 |
Atopic Dermatitis (8) Asthma (4) Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) (1) Perennial Allergic Rhinitis (PAR) (1) Moderate to Severe Chronic Obstructive Pulmonary Disease (1) Healthy (1) Dermatitis, Atopic (1) Nummular Eczema (1) Viral Lung Infection and Acute Respiratory Failure (1) Chronic Obstructive Pulmonary Disease (1)
antibody (4), mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.